Influence of testing modality on bioefficacy for the evaluation of Interceptor® G2 mosquito nets to combat malaria mosquitoes in Tanzania (Publications)
arabiensis: tunnel (OR = 1.42 [95% CI:1.19-1.70], p < 0.001), I-ACT (OR = 1.61 [95% CI: 1.05-2.49], p = 0.031) and hut (OR = 2.53 [95% CI: 1.96-3.26], p < 0.001). Interceptor((R)) and Interceptor((R)) G2 showed
Epidemiology of <em>Schistosoma mansoni</em> infection in Ituri Province, north-eastern Democratic Republic of the Congo (Publications)
knowledge risk factors. Of the 2,131 participants in 2016, 40.0% were positive of S. mansoni infection. Infection prevalence in the villages ranged from 0 to 90.2%. Of the 707 participants in 2017, 73.1% were [...] were tested positive for S. mansoni. Prevalence ranged from 52.8 to 95.0% across the health districts visited. Infection prevalence increased from north to south and from west to east. Exposure to the waters
Characterization of novel antimalarial compound ACT-451840: preclinical assessment of activity and dose-efficacy modeling (Publications)
berghei, respectively. In vitro, ACT-451840 showed a 50% inhibition concentration of 0.4 nM (standard deviation [SD]: +/- 0.0 nM) against the drug-sensitive P. falciparum NF54 strain. The 90% effective doses
High-resolution spatial prediction of anemia risk among children aged 6 to 59 months in low- and middle-income countries (Publications)
estimates, the prevalence of anemia decreased from 65.0% [62.6%-67.4%] in sub-Saharan Africa and 63.1% [60.6%-65.5%] in South Asia in 2010 to 63.4% [60.7%-66.0%] in sub-Saharan Africa and 58.8% [56.4%-61.3%] [...] South Asia in 2020. This translates into approximately 98.7 [94.5-102.8] million and 95.1 [91.1-99.0] million affected children aged 6 to 59 months in 2020, respectively, making it a major public health
The age profile of respiratory syncytial virus burden in preschool children of low- and middle-income countries: a semi-parametric, meta-regression... (Publications)
incidence, probability of hospitalization, or the probability of in-hospital death (p ≤ 0.01, p = 1, p = 0.86, 0.63, respectively). Our study is limited mainly due to the sparsity of the data, especially
Influence of testing modality on bioefficacy for the evaluation of Interceptor® G2 mosquito nets to combat malaria mosquitoes in Tanzania (Publications)
arabiensis: tunnel (OR = 1.42 [95% CI:1.19-1.70], p < 0.001), I-ACT (OR = 1.61 [95% CI: 1.05-2.49], p = 0.031) and hut (OR = 2.53 [95% CI: 1.96-3.26], p < 0.001). Interceptor((R)) and Interceptor((R)) G2 showed
Epidemiology of <em>Schistosoma mansoni</em> infection in Ituri Province, north-eastern Democratic Republic of the Congo (Publications)
knowledge risk factors. Of the 2,131 participants in 2016, 40.0% were positive of S. mansoni infection. Infection prevalence in the villages ranged from 0 to 90.2%. Of the 707 participants in 2017, 73.1% were [...] were tested positive for S. mansoni. Prevalence ranged from 52.8 to 95.0% across the health districts visited. Infection prevalence increased from north to south and from west to east. Exposure to the waters
Characterization of novel antimalarial compound ACT-451840: preclinical assessment of activity and dose-efficacy modeling (Publications)
berghei, respectively. In vitro, ACT-451840 showed a 50% inhibition concentration of 0.4 nM (standard deviation [SD]: +/- 0.0 nM) against the drug-sensitive P. falciparum NF54 strain. The 90% effective doses
Einheit (Korrelationskoeffizient nach Pearson 0.71). Diese Korrelation wurde stärker, wenn die Korrelation auf die bereits abgeschlossener Aktionspläne (rp 0.92) beschränkt wurde, und noch stärker, wenn [...] wenn diese zusätzlich nach dem potentiellen Kundennutzen gewichtet wurden (rp 0.95). Mit diesem positiven Trend hat die Administration aufgezeigt, dass sie fähig ist, adäquat auf Anforderungen aus den Dep
not yet been widely implemented in vaccine development programs to date. The objective of WORMVACS2.0 is to establish an effective pipeline to support helminth vaccine development focusing on schistosomes [...] state-of-the-art immunological profiling to identify correlates and signatures of protection. WORMVACS2.0 will advance scientific and clinical knowledge of host immunity in response to helminth infection, apply
